Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

Authors :: De Smedt R
Peirs S
Morscio J
Matthijssens F
Roels J
Reunes L
Lintermans B
Goossens S
Lammens T
Van Roy N
Touzart A
Jenni S
Tsai YC
Lovisa F
Mussolin L
Serafin V
Van Nieuwerburgh F
Deforce D
Uyttebroeck A
Tousseyn T
Burkhardt B
Klapper W
De Moerloose B
Benoit Y
Macintyre E
Bourquin JP
Basso G
Accordi B
Bornhauser B
Meijerink J
Vandenberghe P
Van Vlierberghe P
Source :: Haematologica [Haematologica] 2019 Jan; Vol. 104 (1), pp. e17-e20. Date of Electronic Publication: 2018 Aug 03.
Publication Year :: 2019

Subjects :: Cell Line, Tumor
Drug Screening Assays, Antitumor
Humans
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma enzymology
Protein Kinase Inhibitors pharmacology
Proto-Oncogene Proteins c-pim-1 antagonists & inhibitors
Proto-Oncogene Proteins c-pim-1 metabolism

Full Text Access

Tools